These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? Bowden NA. Cancer Lett; 2014 May 01; 346(2):163-71. PubMed ID: 24462818 [Abstract] [Full Text] [Related]
26. Platinum compounds in cervical and endometrial cancers: focus on carboplatin. Muggia FM, Muderspach L. Semin Oncol; 1994 Apr 01; 21(2 Suppl 2):35-41; quiz 42, 58. PubMed ID: 8202719 [Abstract] [Full Text] [Related]
27. Dose intensity in advanced ovarian cancer: have we answered the question? Fennelly D. Clin Cancer Res; 1995 Jun 01; 1(6):575-82. PubMed ID: 9816018 [No Abstract] [Full Text] [Related]
28. [Chemotherapy of advanced ovarian carcinoma. II. Second-line treatment and new therapeutic modalities]. Angelini F, Carassai A, Lopez M. Clin Ter; 1989 Apr 30; 129(2):91-104. PubMed ID: 2472913 [Abstract] [Full Text] [Related]
38. [Experimental study on the use of cisplatin in oncology]. Scanni A, Tomirotti M, Campolunghi D, Biraghi M, Curtarelli G. Minerva Med; 1985 Apr 28; 76(17-18):851-7. PubMed ID: 3889721 [Abstract] [Full Text] [Related]
39. Controversies in the management of brain metastases: the role of chemotherapy. Landonio G, Sartore-Bianchi A, Giannetta L, Renga M, Riva M, Siena S. Forum (Genova); 2001 Apr 28; 11(1):59-74. PubMed ID: 11734865 [Abstract] [Full Text] [Related]
40. [Recent advancement of the treatment of urological malignancies]. Akaza H. Gan To Kagaku Ryoho; 1999 Jun 28; 26 Suppl 1():157-64. PubMed ID: 10410670 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]